<DOC>
	<DOCNO>NCT01872624</DOCNO>
	<brief_summary>The combine use one-way endobronchial valve bone-marrow derive mesenchymal stromal cell patient severe pulmonary emphysema safe contribute increase quality life .</brief_summary>
	<brief_title>Safety Study Bone-marrow Derived Mesenchymal Stromal Cells Associated With Endobronchial Valves Emphysema</brief_title>
	<detailed_description>In addition test safety one-way endobronchial valve combine bone-marrow derive mesenchymal stromal cell , study determine systemic inflammatory potential cell therapy measure C-reactive protein level ( CRP ) , erythrocyte sedimentation rate ( ESR ) complete blood count peripheral blood . Finally , study aim determine marker inflammatory response remodel modulate therapy .</detailed_description>
	<mesh_term>Emphysema</mesh_term>
	<mesh_term>Pulmonary Emphysema</mesh_term>
	<criteria>Diagnosis severe heterogeneous emphysema ( heterogeneity &gt; 15 % ) , heterogeneity define difference lobes percent area cover parenchymal density great 950 Hounsfield Units . Estimation collateral ventilation base fissure integrity ≥ 75 % . Total lung capacity &gt; 100 % predict . Residual volume &gt; 150 % predict . Forced expiratory volume first minute &lt; 45 % predict . Diffusing capacity lung carbon monoxide &lt; 45 % predict . Optimal medical treatment . Limitations daily physical activity . Minimum 4 month without smoke Having family support . Stage ≥ 2 modified Medical Research Council Dyspnea Scale ( MMRC ) . Homogenous emphysema . Presence collateral ventilation . Use systemic corticosteroid ( prednisone &gt; 20mg/day equivalent ) . Pulmonary extrapulmonary infection . Coronary heart disease and/or severe ventricular dysfunction . Significant renal liver disease . Immunosuppressive disease . Active smoking . Cancer prognosis survival &lt; 2 year . Psychosocial problem . Pregnancy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>